Table 1 Classification of tumors based on presence of tumor infiltrating lymphocytes (TIL) and PD-L1 expression (based on Teng et al. [9])
From: The role of immune checkpoint inhibition in the treatment of ovarian cancer
Type I: Adaptive immune resistance TIL+ PD-L1+ | Type II: Immunological ignorance TIL- PD-L1- |
Type III: Intrinsic induction TIL- PD-L1+ | Type IV: Tolerance TIL+ PD-L1- |